StockData

InspireMD vs Nexgel

NSPR and NXGL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NSPR and NXGL compare

Nexgel is the larger company, worth 1.2 times as much as InspireMD ($37.0M against $30.2M).

InspireMD grew revenue faster over the last twelve months (53.4% versus 3.4% for Nexgel).

Nexgel keeps more of each dollar of sales as profit, with a net margin of −51.3% compared with −484% at InspireMD.

InspireMD scores higher on the StockData Score (10 against 6 for Nexgel), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNSPRNXGL
Size and price
Market cap$30.2M$37.0M
Share price$0.650$3.80
Change, 1 year−69.2%−90.1%
Change, 5 years−82.1%–
Beta (5Y)−0.871.08
Employees12719
StockData Score
Total score10 (better)6
Valuation score3 (better)2
Growth score2 (better)1
Performance score01 (better)
Health score5 (better)2
Dividend score00
Valuation
P/S2.8× (better)3.1×
P/B1.0× (better)7.5×
FCF yield−141%–
Fair value$1.40$12.33
Margin of safety53.7%69.2% (better)
Growth
Revenue growth (TTM)53.4% (better)3.4%
Revenue growth, 5Y average29.3%76.1% (better)
Profitability
Gross margin18.1%35.1% (better)
Operating margin−494%−44.8% (better)
Net margin−484%−51.3% (better)
FCF margin−392%–
Return on equity−203%−129% (better)
Return on invested capital−4320%−91.0% (better)
Financial health
Debt / equity0.000.09 (better)
Current ratio3.80 (better)0.43
Altman Z-score−11.97−0.89 (better)
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions53.6%9.0%
Held by insiders31.6%13.2%
Insider net buying, 12 months$369K$721K (better)
Short interest, % of float0.79%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.